Abstract

Van Gogh’s attending physicians in the south of France were terse in their hospital entries about his illness.1 Felix Rey, a young intern, still in training at Arles and yet to receive his medical degree, took care of Vincent after his initial crises. Dr. Peyron, onetime military ophthalmologist and now in a second career, gave asylum at St. Rémy. They have received mixed evaluations.

Keywords

Cocaine Neuropathy Tryptophan Propranolol Halothane 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and notes

  1. 1.
    Tralbaut ME. 1981. Vincent van Gogh. New York: The Alpine Fine Arts Collection, Ltd.Google Scholar
  2. 2.
    For this point of view see Gastaut H. 1956. La maladie de Vincent van Gogh envisagée à la lumière des conceptions nouvelles sur l’épilepsie psychomotrice. Annales Medico-Psychologiques vol 1 for 1956: 196–238; wherein Dr. Aussoliel, a friend of Dr. Rey, was deemed to be a local expert on masked epilepsy.Google Scholar
  3. 3.
    Voskuil PHA. 1983. The epilepsy of Fyodor Mikhailovitch Dostoevsky (1821–1881). Epilepsia 24: 658–667.CrossRefGoogle Scholar
  4. 4.
    Lubin AJ. 1987. Stranger on the Earth: A Psychological Biography of Vincent van Gogh. New York: Henry Holt & Co.Google Scholar
  5. 5.
    Arnold WN. 1988. Vincent van Gogh and the thujone connection. Journal of the American Medical Association 260: 3042–3044.CrossRefGoogle Scholar
  6. 6.
    Loftus LS Sc Arnold WN. 1991. Vincent van Gogh’s illness: acute intermittent porphyria? British Medical Journal 303: 1589–1591.CrossRefGoogle Scholar
  7. 7.
    The Complete Letters of Vincent van Gogh. 2nd ed., 1978. Boston: New York Graphic Society.Google Scholar
  8. 8.
    Hemphill RE. 1961. The illness of Vincent van Gogh. Proceedings of the Royal Society of Medicine 54: 1083–1088.Google Scholar
  9. 9.
    Tralbaut ME. op. cit. pp l77–l78.Google Scholar
  10. 10.
    Tralbaut ME. op. cit. p 276.Google Scholar
  11. 11.
    van Gogh-Bonger J. 1978. Memoir of Vincent van Gogh, vol I, pp XLV-XLVI, in: The Complete Letters of Vincent van Gogh. 2nd ed. Boston: New York Graphic Society.Google Scholar
  12. 12.
    Stokvis BJ. 1889. Over twee zeldzame kleurstoffen in urine van zieken. Weekblad van het Nederlandsch Tijdschrift voor Geneeskunde 2: 409–417.Google Scholar
  13. 13.
    With TK. 1980. A short history of porphyrins and the porphyrias. Internationalfournal of Biochemistry 11: 189–200.CrossRefGoogle Scholar
  14. 14.
    Waldenstrom J. 1957. The porphyrias as inborn errors of metabolism. American Journal of Medicine 22: 758–773.CrossRefGoogle Scholar
  15. 15.
    Tishler PV, Woodward B, O’Connor J, Holbrook DA, Seidman LJ, Hallett M Sc Knighton DJ. 1985. High prevalence of intermittent acute porphyria in a psychiatric patient population. American Journal of Psychiatry 142: 1430–1436.Google Scholar
  16. 16.
    Bonkovsky HL, Sinclair PR, Emery S Sc Sinclair JF. 1980. Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology 30: 588–592.Google Scholar
  17. 17.
    Ivers WM. 1951. Acute intermittent porphyria. Journal of Urology 66: 816–818.Google Scholar
  18. 18.
    Grossfeld E. 1951. Acute porphyria with unusual features. British MedicalJaurnalVol I for 1951: 1240–1241.CrossRefGoogle Scholar
  19. 19.
    Sack GH. Jr. 1990. Acute intermittent porphyria. Journal of the American Medical Association 264: 1290–1293.CrossRefGoogle Scholar
  20. 20.
    Kappas A, Sassa S, Galbraith RA & Nordmann Y. 1989. The porphyrias, pp 1305–1365, in: The Metabolic Basis of Inherited Disease. 6th ed. CR Scriver, AL Beaudet, WS Sly & D Valle (eds.) New York: McGraw-Hill.Google Scholar
  21. 21.
    Laiwah AACY, Mactier R, McColl KEL, Moore MR Sc Goldberg A. 1983. Early-onset chronic renal failure as a complication of acute intermittent porphyria. Quarterly Journal of Medicine 52: 92–98.Google Scholar
  22. 22.
    Lai CW, Hung TP Se Lin WSJ. 1977. Blindness of cerebral origin in acute intermittent porphyria. Archives of Neurology 34: 310–312.Google Scholar
  23. 23.
    Ridley A. 1969. The neuropathy of acute intermittent porphyria. The Quarterly Journal of Medicine 38: 307–333.Google Scholar
  24. 24.
    Moore MR. 1980. International review of drugs in acute porphyria. International Journal of Biochemistry 12: 1089–1097.CrossRefGoogle Scholar
  25. 25.
    Welland FH, Hellman ES, Gaddis EM, Collins A, Hunter GWJr. & Tschudy DR 1964. Factors affecting the excretion of porphyrin precursors by patients with acute intermittent porphyria. I. The effect of diet. Metabolism 13: 232–250.CrossRefGoogle Scholar
  26. 26.
    Knudsen KB, Sparberg M & Lecocq F. 1967. Porphyria precipitated by fasting. New England Journal of Medicine 277: 350–351.CrossRefGoogle Scholar
  27. 27.
    Lip GYH, McColl KEL, Goldberg A & Moore MR. 1991. Smoking and recurrent attacks of acute intermittent porphyria. British Medical Journal 302: 507.CrossRefGoogle Scholar
  28. 28.
    Bickers DR, Miller L & Kappas A. 1975. Exacerbation of hereditary hepatic porphyria by surreptitious ingestion of an unusual provocative agent, a mouthwash preparation. New England Journal of Medicine 292: 1115–1116.CrossRefGoogle Scholar
  29. 29.
    Goldberg A & Rimington C. 1962. Diseases of Porphyrin Metabolism, pp 64–109. Springfield: C.C. Thomas.Google Scholar
  30. 30.
    Battersby AR, Fookes CJR, Matcham GWJ & McDonald E. 1980. Biosynthesis of the pigments of life: formation of the macrocycle. Nature 285: 17–21.CrossRefGoogle Scholar
  31. 31.
    LascellesJ. 1960. The synthesis of enzymes concerned in bacteriochlorophyll formation in growing cultures of Rhodopseudomonas spheroides. Journal of General Microbiology 23: 487–498.Google Scholar
  32. 32.
    Scholnick PL, Hammaker LE & Marver HS. 1969. Soluble hepatic 5-aminolevulinic acid synthetase: end-product inhibition of the partially purified enzyme. Proceedings of the National Academy of Sciences (USA) 63: 65–70.CrossRefGoogle Scholar
  33. 33.
    Tschudy DP, Welland FH, Collins A & Hunter GJr. 1964. The effect of carbohydrate feeding on the induction of 5-aminolevulinic acid synthetase. Metabolism 13: 396–406.CrossRefGoogle Scholar
  34. 34.
    Sassa S, Bradlow HL & Kappas A. 1979. Steroid induction of 5-aminolevulinic acid synthase and porphyrins in liver: structure-activity studies on the permissive effects of hormones on the induction process. Journal of Biological Chemistry 254: 10011–10020.Google Scholar
  35. 35.
    Strand LJ, Felsher BF, Redeker AG & Marver HS. 1970. Enzymatic abnormality in heme biosynthesis in acute intermittent porphyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased 5-aminolevulinic acid synthetase activity. Proceedings of the National Academy of Sciences (USA) 67: 1315–1320.CrossRefGoogle Scholar
  36. 36.
    Magnussen CR, Levine JB, DohertyJM, Cheesman JO & Tschudy DP. 1974. A red cell enzyme method for the diagnosis of acute intermittent porphyria. Blood 44: 857–868.Google Scholar
  37. 37.
    Becker DM & Kramer S. 1977. The neurological manifestations of porphyria: a review. Medicine 56: 411–423.CrossRefGoogle Scholar
  38. 38.
    Müller WE & Snyder SH. 1977. 5-Aminolevulinic acid: influences on synaptic GABA receptor binding may explain CNS symptoms of porphyria. Annals of Neurology 2: 340–342.CrossRefGoogle Scholar
  39. 39.
    Meyer UA, Strand LJ, Doss M, Rees AC & Marver HS. 1972. Intermittent acute porphyria: demonstration of a genetic defect in porphobilinogen metabolism. New England Journal of Medicine 286: 1277–1282.CrossRefGoogle Scholar
  40. 40.
    Litman DA & Correia MA. 1985. Elevated brain tryptophan and enhanced 5-hydroxy- tryptamine turnover in acute hepatic heme deficiency: clinical implications. Journal of Pharmacology and Experimental Therapeutics 232: 337–345.Google Scholar
  41. 41.
    Tschudy DP, Valsamis M & Magnussen CR. 1975. Acute intermittent porphyria: clinical and selected research aspects. Annals of Internal Medicine 83: 851–864.Google Scholar
  42. 42.
    Meyer UA & Schmid R. 1978. The porphyrias, pp 1160–1220, in: The Metabolic Basis of Inherited Disease. 4th ed. JB Stanbury, JB Wyngaarden and DS Fredrickson (eds.) New York: McGraw-Hill Book Company.Google Scholar
  43. 43.
    Lieber CS, Teschke R, Hasumura Y & Decarli LM. 1975. Differences in hepatic and metabolic changes after acute and chronic alcohol consumption. Federation Proceedings 34: 2060–2074.Google Scholar
  44. 44.
    Granick S. 1966. The induction in vitro of the synthesis of ô-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals. Journal of Biological Chemistry 241: 1359–1375.Google Scholar
  45. 45.
    Mustajoki P & Koskelo P. 1976. Hereditary hepatic porphyrias in Finland. Acta Medica Scandinavica 200: 171–178.CrossRefGoogle Scholar
  46. 46.
    Barker LF & Estes WL. 1912. Family hematoporphyrinuria in association with chronic gastroduodenal dilation, peculiar fits and acute polyneuritis: a preliminary report. Journal of the American Medical Association 59: 718–719.Google Scholar
  47. 47.
    Waldenström J. 1937. Studien ueber Porphyrie. Acta Medica Scandinavica 82 (suppl.): 1–254.Google Scholar
  48. 48.
    Gates RR. 1946. Human Genetics. New York: Macmillan.Google Scholar
  49. 49.
    Wang A-L, Arredondo-Vega FX, Giampietro PF, Smith M, Anderson WF & Desnick RJ. 1981. Regional gene assignment for human porphobilinogen deaminase and esterase-A4 to chromosome llq23→11qter. Proceedings of the National Academy of Sciences (USA) 78: 5734–5738.CrossRefGoogle Scholar
  50. 50.
    Mustajoki P & Desnick RJ. 1985. Genetic heterogeneity in acute intermittent porphyria: characterisation and frequency of porphobilinogen deaminase mutations in Finland. British Medical Journal 291: 505–509.CrossRefGoogle Scholar
  51. 51.
    Kappas A, Bradlow HL, Bickers DR & Alvares AP. 1977. Induction of a deficiency of steroid A4–5-a-reductase activity in liver by a porphyrin gene. Journal of Clinical Investigation 59: 159–169.CrossRefGoogle Scholar
  52. 52.
    Becker B, Shin DH, Palmberg PF & Waltman SR. 1976. H LA antigens and corti¬costeroid response. Science 194: 1427–1437.CrossRefGoogle Scholar
  53. 53.
    Herrick AL, McColl KEL, Wallace AM, Moore MR & Goldberg A. 1990. Elevation of hormone-binding globulins in acute intermittent porphyria. Clinica Chimica Acta 187: 141–148.CrossRefGoogle Scholar
  54. 54.
    Grandchamp B, de Verneuil H, Beaumont C, Chretien S, Walter O & Nordmann Y. 1987. Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene. European Journal of Biochemistry 162: 105–110.Google Scholar
  55. 55.
    Grandchamp B, Picat C, Kauppinen R, Mignotte V, Peltonen L, Mustajoki P, Roméo PH, Goossens M & Nordmann Y. 1989. Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase. European Journal of Clinical Investigation 19: 415–418.CrossRefGoogle Scholar
  56. 56.
    Grandchamp B, Picat C, Mignotte V, Wilson JHP, Te Velde K, Sandkuyl L, Roméo PH, Goossens M & Nordmann Y 1989. Tissue-specific splicing mutation in acute intermittent porphyria. Proceedings of the National Academy of Sciences (USA) 86: 661–664.CrossRefGoogle Scholar
  57. 57.
    Goldberg A. 1985. Molecular genetics of acute intermittent porphyria. British Medical Journal 291: 499–500.CrossRefGoogle Scholar
  58. 58.
    Tralbaut ME. loc.dt. pp. 16–17.Google Scholar

Copyright information

© Birkhäuser Boston 1992

Authors and Affiliations

  • Wilfred Niels Arnold

There are no affiliations available

Personalised recommendations